If you sold on Thursday, you already had a GOOD, nice gain on it. <g>
Albeit not as much as mine so far on CBIO. :-)
However, although MNKD was down 26.58% on Friday on a volume of 19,449,149
It was still up 12.05% for the week, and the volume on Thursday, which was a GOOD up day, of 32,692.380 was also higher than the one on Friday. So I don't think selling it short now would be a GOOD move.<g>
The analyst consensus target is $7, but the stock still needs to close above Thursday H of 4.05 and then the Oct 10 H of 6.96 <g>
Also according to an article on Forbes, Nate Pile has been buying and thinks that MannKind has become the most extreme example of "market inefficiency" he has seen in his 30 years of following the biotech sector.<g>
He thinks that although the shorts have been in control for some time, MNKD has a number of potential catalysts on the near-term horizon, and he thinks that the stock is still cheap.<g>
And the stock is still up 20.26% on a monthly basis, <g>
https://stockcharts.com/c-sc/sc?s=MNKD&p=M&b=5&g=0&i=t56074224139&r=1517181674494
And if on a close above March 2016 H of 11.20, it seems that it would have plenty of room still to run.<g>
https://elite.finviz.com/chart.ashx?t=MNKD&ty=c&ta=0&p=m&s=l
RAGL,
Bernard
|
